Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from Ga-DOTATOC PET/CT in Well-Differentiated Neuroendocrine Tumors.

Our objective was to evaluate the prognostic value of somatostatin receptor tumor burden on Ga-DOTATOC PET/CT in patients with well-differentiated (WD) neuroendocrine tumors (NETs). We retrospectively analyzed the Ga-DOTATOC PET/CT scans of 84 patients with histologically confirmed WD NETs (51 grade 1, 30 grade 2, and 3 grade 3). For each PET/CT scan, all Ga-DOTATOC-avid lesions were independently segmented by 2 operators using a customized threshold based on the healthy liver SUV (LIFEx, version 5.1). Somatostatin receptor-expressing tumor volume (SRETV) and total lesion somatostatin receptor expression (TLSRE = SRETV × SUV) were extracted for each lesion, and then whole-body SRETV and TLSRE (SRETVwb and TLSREwb, respectively) were defined as the sum of SRETV and TLSRE, respectively, for all segmented lesions in each patient. Time to progression (TTP) was defined as the combination of disease-free survival in patients undergoing curative surgery ( = 10) and progression-free survival for patients with unresectable or metastatic disease ( = 74). TTP and overall survival were calculated by Kaplan-Meier analysis, log-rank testing, and the Cox proportional-hazards regression model. After a median follow-up of 15.5 mo, disease progression was confirmed in 35 patients (41.7%) and 14 patients died. A higher SRETVwb (>39.1 cm) and TLSREwb (>306.8 g) correlated significantly with a shorter median TTP (12 mo vs. not reached; < 0.001). In multivariate analysis, SRETVwb ( = 0.005) was the only independent predictor of TTP regardless of histopathologic grade and TNM staging. According to our results, SRETVwb and TLSREwb extracted from Ga-DOTATOC PET/CT could predict TTP or overall survival and might have important clinical utility in the management of patients with WD NETs.